GBS

DXC Technology Named a Strong Performer in Whitelane Research's 2023/2024 European IT Sourcing Study

Retrieved on: 
Friday, February 2, 2024
DXC Technology, Research, Public sector, DXC, Corporate services, Annual report, GBS, Artificial intelligence, IBM Consulting, Trust, Risk

ASHBURN, Va., Feb. 2, 2024 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has secured a top five position in Whitelane Research's 2023/2024 European IT Sourcing Study. It is the second successive year that DXC has improved its ranking, demonstrating its continued commitment to delivering value and excellence for its customers.

Key Points: 
  • ASHBURN, Va., Feb. 2, 2024 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, has secured a top five position in Whitelane Research's 2023/2024 European IT Sourcing Study.
  • It is the second successive year that DXC has improved its ranking, demonstrating its continued commitment to delivering value and excellence for its customers.
  • Whitelane Research, one of the most prestigious research organizations in Europe, surveyed over 2,000 businesses and public sector organizations spanning eight European countries and regions.
  • "We are very impressed with the consistent progress DXC is making each year," commented Jef Loos, Head of Research Europe at Whitelane Research.

Vintage Investment Partners Announces Two New Members of Its Strategic Advisory Board

Retrieved on: 
Tuesday, January 30, 2024
Entrepreneurship, Senior, Presidency of Barack Obama, GBS, National Council, Former, Hadassah Medical Center, Research, Ovarian cancer, Hebrew University of Jerusalem, Bank, Genius, CFA, Bank of Israel, University, LLB, Fidelity, Central Waqf Council, Economics, PGD, P&G, Education, Strauss Group, MIT, Berkshire Partners, Analysis Group, SAB, Bank Leumi, GMO, CDPQ, Finance, Harvard University, Doctor of Philosophy, First Nations in Manitoba, Cincinnati metropolitan area, Defense, IBM Consulting, Bed Bath & Beyond, Teaching, Management

Dr. Haj-Yehia served between 2019-2023 as Executive Group Chairman of Bank Leumi, the largest and oldest bank in Israel.

Key Points: 
  • Dr. Haj-Yehia served between 2019-2023 as Executive Group Chairman of Bank Leumi, the largest and oldest bank in Israel.
  • "I am thrilled to have Samer and Andy join our Strategic Advisory Board.
  • More importantly, both bring unique experience and perspectives to Vintage that we are thrilled to tap", said Alan Feld, Founder and Co-Managing Partner of Vintage.
  • The other members of the Vintage SAB include: Bradley Bloom, Former Chairman and Co-Founder of Berkshire Partners, Mark Dubowitz, CEO, Foundation for the Defense of Democracies, Ambassador S. Fitzgerald Haney, Former U.S.

New York Life Launches Voluntary Benefits Designed to Support Employees’ Financial Wellbeing

Retrieved on: 
Monday, January 29, 2024
Professional Services, Health, Insurance, Health Insurance, Human Resources, Personal Finance, Senior, GBS, Travel, Research, Pet, NYL, Health insurance

New York Life today announced the launch of a new portfolio of voluntary benefits , aimed at enhancing employees' financial security.

Key Points: 
  • New York Life today announced the launch of a new portfolio of voluntary benefits , aimed at enhancing employees' financial security.
  • These benefits include accident, critical illness, and hospital indemnity insurance and will be available to employers through New York Life Group Benefit Solutions (NYL GBS).
  • New York Life's voluntary benefits are designed to mitigate these challenges, offering employee-centric, tailored plans that cover more medical conditions and treatments while reducing administrative complexity for employers.
  • “These solutions have been designed to be used, not forgotten.”
    The new voluntary benefit offerings from New York Life enable a more seamless connected benefits experience.

inTEST Appoints Michael Goodrich as President, Process Technologies Division

Retrieved on: 
Tuesday, January 16, 2024
Technology, Contracts, Semiconductor, Automotive, General Automotive, Automotive Manufacturing, Telecommunications, Aerospace, Manufacturing, Defense, GBS, DeVry University, OSRAM, Operation, University, Mentorship, Electrical engineering technology, Organization, Marketing, Management

inTEST Corporation (NYSE American: INTT), a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target markets which include automotive/EV, defense/aerospace, industrial, life sciences, security, and semiconductor (“semi”), announced today the appointment of Michael Goodrich to the position of President, Process Technologies Division.

Key Points: 
  • inTEST Corporation (NYSE American: INTT), a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target markets which include automotive/EV, defense/aerospace, industrial, life sciences, security, and semiconductor (“semi”), announced today the appointment of Michael Goodrich to the position of President, Process Technologies Division.
  • Mr. Goodrich is a global technology leader with proven experience leading international cross-function teams in technology and manufacturing organizations.
  • Previous to that he was President of GBS, LLC providing strategic and process improvement advisory services to technology and manufacturing business.
  • Mr. Goodrich spent over 20 years of his career at Rudoph Technologies where he progressively advanced to roles of greater responsibility.

Positioning Asia's Shared Services as Engines of Transformation and Innovation

Retrieved on: 
Tuesday, January 9, 2024
Intelligent automation, Shared services, Conference, Synthetic media, GBS, SSO, HR, Generative, DEI, Growth, N-hydroxythioamide S-beta-glucosyltransferase, Equality, Automation

The 27th Asian Shared Services & Outsourcing Week 2024 is committed to congregate the region's shared services thought leaders, decision makers, influencers, across various functions such as IT, HR, Procurement, Strategy, Operations, and many more.

Key Points: 
  • The 27th Asian Shared Services & Outsourcing Week 2024 is committed to congregate the region's shared services thought leaders, decision makers, influencers, across various functions such as IT, HR, Procurement, Strategy, Operations, and many more.
  • 27th Asian Shared Services & Outsourcing Week 2024, the #1 Regional Shared Services Event spanning across four action-packed days, is proud to present an ensemble of 50+ distinguished speakers and an impressive 140+ regional shared services thought leaders.
  • For businesses seeking to showcase their technological solutions and services, 27th Asian Shared Services & Outsourcing Week 2024 is now open for sponsorship opportunities -thought leadership slots and booths.
  • Sponsors will have exclusive opportunities to demonstrate thought leadership and engage with Shared Services leaders in the region.

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Retrieved on: 
Monday, January 8, 2024
Patient, Geographic atrophy, Initiate, Conference, Outline, ARCHER, Immunoglobulin therapy, GBS, PRIME, EMA, Research, Paratriathlon, Cold agglutinin disease, AMD, CAD, Complement component 1s, Brain, Facial muscles, Eye, Clinical trial, Inflammation, Pharmacokinetics, Nerve, Death, Nervous system, Guillain, SAD, Complement component 1q, Webcast, Safety, Meta-analysis, Pharmaceutical industry

BRISBANE, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today outlined its strategic priorities for 2024 with late-stage clinical milestones, including ANX005 for Guillain-Barré syndrome (GBS), ANX007 for geographic atrophy (GA) and its first-in-kind oral small molecule complement inhibitor, ANX1502, for a range of autoimmune indications.

Key Points: 
  • The study completed enrollment in 2023 and the company is on-track to report Phase 3 data in the first half of 2024.
  • Annexon also plans to initiate the ARROW clinical trial, an injection-controlled head-to-head study against SYFOVRE® (pegcetacoplan injection) in late 2024.
  • A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com.
  • A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

The 24th Hong Kong Forum concludes successfully

Retrieved on: 
Wednesday, December 6, 2023
Health, Biotechnology, GBS, Gleneagles Hong Kong Hospital, Forum, HKTDC, HKSAR, Adviser, SME, GBM, Film industry

HONG KONG, Dec 6, 2023 - (ACN Newswire) - The 24th Hong Kong Forum,

Key Points: 
  • HONG KONG, Dec 6, 2023 - (ACN Newswire) - The 24th Hong Kong Forum,
    business leaders from 26 countries and regions.
  • "It is clear that in the short term, Hong Kong will face
    some headwinds in light of the global geo-economic fragmentation.
  • Officer of Gleneagles Hong Kong Hospital, explored prospects for
    healthcare and biotechnology in Hong Kong.
  • In addition to the Forum, FHKBAW's overseas member associates
    visited key development projects in Hong Kong, including the Kai
    The Hong Kong Forum is the FHKBAW's annual flagship event.

Daythree Achieves Remarkable Growth, with a Record RM66.3 Million in Revenue

Retrieved on: 
Thursday, November 23, 2023
Hospitality, Digital, Faith, PBT, GBS, IBM Consulting, Automation, Financial services, Energy, RM, Optimism, Growth, Travel, Automotive industry, Retail, Climate, YTD, Rare-earth element

KUALA LUMPUR, Nov 23, 2023 - (ACN Newswire) - Daythree Digital Berhad ("Daythree" or the "Group"), a leading Global Business Services ("GBS") provider, has announced a robust year-to-date ("YTD") revenue of RM66.3 million, eclipsing the total revenue of RM65.1 million for FY2022.

Key Points: 
  • KUALA LUMPUR, Nov 23, 2023 - (ACN Newswire) - Daythree Digital Berhad ("Daythree" or the "Group"), a leading Global Business Services ("GBS") provider, has announced a robust year-to-date ("YTD") revenue of RM66.3 million, eclipsing the total revenue of RM65.1 million for FY2022.
  • This impressive performance is anchored by the Energy and Utilities segment, contributing RM28.9 million, or 43.6% of the total revenue, demonstrating Daythree's resilient revenue growth amidst challenging market conditions.
  • Daythree reported a gross profit of RM5.0 million in Q3, down from RM6.3 million in the preceding quarter.
  • The Group's profit before taxation ("PBT") stood at RM1.8 million, a decrease from RM3.6 million in the preceding quarter, primarily due to non-recurring listing expenses of RM1.2 million.

"Yahoo! Finance Invest - Beyond Borders: Collaborating for Financial Excellence" Returns with Impressive Online Viewership of over 600,000

Retrieved on: 
Thursday, November 16, 2023
Crypto, Policy, Entrepreneurship, Imagination, InvestHK, Blockchain, Culture, Motivation, Financial centre, Fintech, Athlete, GM, GBS, Terminal 3, HKTDC, Financial services, Brain, Legislation, Freedom, Central government, Tennis, AI, Mental health, Yahoo!, Beyond Borders, Attitude, GBM, Finance, Legislative council, Creativity, GBA, Life

The conference, held on November 14, captivated a global audience, attracting an impressive viewership of over 600,000 within the first 4 hours of live broadcasting.

Key Points: 
  • The conference, held on November 14, captivated a global audience, attracting an impressive viewership of over 600,000 within the first 4 hours of live broadcasting.
  • Themed "Beyond Borders: Collaborating for Financial Excellence", the event brought together distinguished business leaders and speakers from across the globe at the forefront of investment and technology trends.
  • These esteemed individuals shared their expertise and provided market updates, enriching the conference experience for attendees.
  • Finance Invest 2023 has recorded more than 600,000 online viewership worldwide within the first 4 hours of live broadcasting.

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Molecule, Ophthalmology, Visual acuity, Investment, HD, EMA, Research, Kidney, Autoimmune disease, Driver, C3, Conference, R, Facial muscles, Inflammation, Treatment, Meta-analysis, American Academy, American Society of Nephrology, G&A, Guillain, Society, Letter, Paratriathlon, European Medicines Agency, American Academy of Ophthalmology, Professional, C4, AAO, System, Nephrology, AMD, Immunoglobulin therapy, PACA, Plasma, Disease, Complement component 1q, Medicine, Complement system, FDA, Geographic atrophy, GBS, ARCHER, C5, HIV disease progression rates, Risk management, Pharmaceutical industry, Vaccine, Cryptocurrency, Patient, LN, ALS

EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.

Key Points: 
  • EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.
  • Importantly, Annexon also announced that it has achieved target enrollment of 225 patients in the randomized, double-blind, placebo-controlled Phase 3 trial of ANX005 in patients with GBS.
  • Research and development (R&D) expenses: R&D expenses were $27.9 million for the quarter ended September 30, 2023, reflecting the advancement of the company’s priority programs, including GBS, GA and ANX1502, compared to $27.9 million for the quarter ended September 30, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $6.9 million for the quarter ended September 30, 2023, compared to $8.2 million for the quarter ended September 30, 2022.